Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.61 |
| ▸ | MERTK | Q12866 | 1/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.61 |
| ▸ | AXL | P30530 | 1/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30324496 | 0.91 | PIK3CG (0.60) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL975785 | 0.91 | PIK3CG (0.60) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL30133702 | 0.91 | PIK3CG (0.60) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL976027 | 0.91 | PIK3CG (0.60) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL25210611 | 0.88 | PIK3CG (0.64) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL30133637 | 0.88 | PIK3CG (0.64) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL18236141 | 0.88 | PIK3CD (0.64) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL25267326 | 0.88 | PIK3CG (0.64) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL30324726 | 0.88 | PIK3CG (0.64) | PIK3CDPIK3CGMERTKPIK3R1AXL | |
| SCHEMBL975035 | 0.87 | PIK3CD (0.63) | PIK3CDPIK3CGMERTKPIK3R1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732097-B2 | Process for the synthesis of a phosphoinositide 3-kinase inhibitor | INCYTE CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160362426-A1 | PROCESS FOR THE SYNTHESIS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR | INCYTE CORPORATION | 2016-12-15 | — | — | US | disclosed |
| EP-2448938-B1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORP (US) | 2014-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362426-A1 | PROCESS FOR THE SYNTHESIS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR | PIK3CA, PI4KA, PIK3CD | PIK3CD 3/4885PIK3CG 10/4885MERTK 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.